Status and phase
Conditions
Treatments
About
Our study the NSCLC harbors EGFR-mutation with Conmana combined with thalidomide as first-line treatment, is expected to improve further EGFR-Tyrosine kinase inhibitors (TKI) response rate (ORR), prolong time to progression (PFS), improve patient survival.
Full description
Primary Objective:
To evaluate the efficacy, survival and side effects of the combined therapy, and to evaluate the effectiveness and safety of thalidomide with Conmana in patients who harbors EGFR mutations.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
67 participants in 1 patient group
Loading...
Central trial contact
an yunxia; zhang xiaoju
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal